NCT00480272View on ClinicalTrials.gov

Prospective Study on Intensive Early Rheumatoid Arthritis Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

March 1, 2017

Study Completion Date

March 1, 2017

Conditions
Rheumatoid Arthritis
Interventions
DRUG

adalimumab, plus prednisone

adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo or prednisone 50 mg/po day then reduced to 6.25/po day

DRUG

adalimumab plus placebo

adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo daily for 6 months

Trial Locations (1)

27100

IRCCS S. Matteo Hospital, Pavia

All Listed Sponsors
lead

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER

NCT00480272 - Prospective Study on Intensive Early Rheumatoid Arthritis Treatment | Biotech Hunter | Biotech Hunter